Mapping the Progress of Alzheimer’s and Parkinson’s DiseaseYoshikuni Mizuno, Abraham Fisher, Israel Hanin Springer Science & Business Media, 31 мар. 2002 г. - Всего страниц: 566 1h The 5 International Conference on the Progress in Alzheimer's Disease and Parkinson's 51 1 Disease took place from March 31 to April 5 \ 2001 in Kroto, Japan. This international 1 conference was organized as a joint Congress with the 9 International Catecholamine Symposium. A total of 1258 clinicians and researchers participated in this joint congress 1h from 38 countries in the world. This book represents the proceedings of the 5 Conference on Alzheimer's and Parkinson's disease. The International Conference on the Progress in Alzheimer's and Parkinson's disease was first launched by Professor Abraham Fisher of Israel and Professor Israel Hanin of USA. The first conference was held in Eilat, Israel in 1985. The second conference was organized in Kyoto, Japan in 1989; the third one in Chicago, USA, in 1993, and the fourth one in Eilat, Israel in 1997. The International Catecholamine Symposium (ICS) is an international meeting devoted to the development of basic as well as clinical research on catecholamines. The first Catecholamine Symposium was held in Bethesda, USA in 1958. Since then this symposium has occurred every 5 years. Professor Toshiharu Nagatsu was appointed as 1h the president of the 9 International Catecholamine Symposium, which was to be held in 200 I also in Japan. Therefore, we decided to organize a joint congress of the two meetings, because there is much overlap in research between Alzheimer's disease, Parkinson's disease, and catecholamines. We thank Professor Nagatsu very much for agreeing to organizing this joint congress. |
Содержание
1 | |
13 | |
19 | |
27 | |
33 | |
39 | |
NEURONAL SURVIVAL AND DEATH IN ALZHEIMER DISEASE | 49 |
A STRUCTUREFUNCTION | 65 |
UBIQUITINPROTEASOME PATHWAY IS A KEY TO UNDERSTANDING | 291 |
COLOCALIZATION OF PARKIN WITH αSYNUCLEIN IN THE LEWY | 297 |
A SHORT HISTORY OF DOPAMINE AND LEVODOPA | 305 |
FAMOUS PEOPLE WITH PARKINSON DISEASE | 311 |
CLINICAL EVALUATION AND DIFFERENTIAL DIAGNOSIS | 321 |
GAIT DISTURBANCES IN PARKINSONS DISEASE | 329 |
LEVODOPA DOES NOT ENHANCE NIGRAL DEGENERATION | 337 |
AUTONOMIC DISORDERS AND MALIGNANT SYNDROME | 349 |
PS1 INTERACTS WITH AND FACILITATES BCATENIN TURNOVER 73 | 72 |
BSECRETASE A TARGET FOR ALZHEIMERS DISEASE | 79 |
PRESENILIN DEPENDENT ySECRETASE PROCESSING OF ẞAMYLOID | 91 |
PS1 IS TRANSPORTED FROM THE MOTONEURONS TO THEIR AXON | 101 |
PRESENILIN1 FUNCTION IN THE ADULT BRAIN | 111 |
NEUROPEPTIDE EXPRESSION IN ANIMAL DISEASE MODELS | 117 |
AMYLOID PATHOLOGY AND CHOLINERGIC NETWORKS | 127 |
INTERACTIONS OF BETAAMYLOID WITH THE FORMATION | 139 |
HISTORICAL OVERVIEW OF GLYCOSAMINOGLYCANS GAGs | 145 |
POTENTIAL ROLE | 157 |
LOW MOLECULAR WEIGHT GLYCOSAMINOGLYCAN BLOCKADE | 165 |
C3 A PROMISING ULTRA LOW MOLECULAR WEIGHT | 171 |
MILD COGNITIVE IMPAIRMENT | 177 |
FUNCTIONAL ACTIVATION STUDIES IN ALZHEIMER PATIENTS | 183 |
THE NEW GENERATION OF ACETYLCHOLINESTERASE INHIBITORS | 193 |
M1 MUSCARINIC AGONISTS AS A THERAPEUTIC STRATEGY | 205 |
PHENSERINE REGULATES TRANSLATION OF BAMYLOID | 211 |
DEVELOPMENT OF ANTIDEMENTIA DRUGS FOR ALZHEIMERS | 223 |
HUMAN NEURAL STEM CELL TRANSPLANTATION IMPROVES | 229 |
BiPGRP78INDUCED MICROGLIAL ACTIVATION AND INCREASE | 235 |
PARKINSONS DISEASE NEUROTOXINS AND THE DOPAMINE | 245 |
GENETIC RISK FACTORS IN PARKINSONS DISEASE | 251 |
INFLAMMATORY CHANGES AND APOPTOSIS IN PARKINSONS | 259 |
CHRONIC COMPLEX 1 INHIBITION REPRODUCES FEATURES | 271 |
NEUTRAL RSALSOLINOL NMETHYLTRANSFERASE AS | 277 |
FAMILIAL PARKINSONISM WITH APATHY DEPRESSION | 285 |
PROGRESS IN THE TREATMENT OF PARKINSONS DISEASE | 361 |
NEUROPROTECTION IN PARKINSONS DISEASE | 373 |
SUSTAINED DOPAMINE AGONISM WITH CABERGOLINE | 379 |
SLEEPINESS AND SLEEP ATTACKS IN PARKINSONS DISEASE | 385 |
NEUROPROTECTION BY DOPAMINE AGONISTS AND APPLICATION | 391 |
PROBLEMS OF LONGTERM LEVODOPA TREATMENT | 397 |
EVALUATION OF ABNORMAL INVOLUNTARY MOVEMENTS | 403 |
MANAGEMENT OF ANXIETY AND DEPRESSION IN PARKINSONS | 417 |
TANDOSPIRONE CITRATE A NEW SEROTONERGIC ANXIOLYTIC | 423 |
STEREOTACTIC SURGERY OF PARKINSONS DISEASE OVER | 429 |
SURGICAL TREATMENT FOR DYSKINESIAS | 435 |
DEEP BRAIN STIMULATION AND NEUROPROTECTION | 441 |
CYCLIC GMPMEDIATED PRECONDITIONING GENE INDUCTION AS | 447 |
NEUROPROTECTIVE PROPERTIES OF GPI1046 A NON | 455 |
FK506 PROTECTS DOPAMINERGIC DEGENERATION THROUGH | 463 |
DEMENTIA WITH LEWY BODIES | 473 |
CHOLINERGIC AND MONOAMINERGIC CORRELATES OF CLINICAL | 491 |
DEMENTIA WITH LEWY | 497 |
ACCUMULATION OF INSOLUBLE αSYNUCLEIN IN HUMAN LEWY | 509 |
ALTERNATIVE TREATMENTS FOR LEWY BODY DISEASE | 513 |
THE NEUROPATHOLOGY OF FRONTOTEMPORAL LOBAR | 523 |
PROGRESS IN PSP AND CBD | 531 |
BIOCHEMICAL ANALYSIS OF TAU AND αSYNUCLEIN | 537 |
INDEX | 549 |
Другие издания - Просмотреть все
Mapping the Progress of Alzheimer’s and Parkinson’s Disease Yoshikuni Mizuno,Abraham Fisher,Israel Hanin Ограниченный просмотр - 2002 |
Mapping the Progress of Alzheimer’s and Parkinson’s Disease Yoshikuni Mizuno,Abraham Fisher,Israel Hanin Недоступно для просмотра - 2013 |
Mapping the Progress of Alzheimer’s and Parkinson’s Disease Yoshikuni Mizuno,Abraham Fisher,Israel Hanin Недоступно для просмотра - 2012 |
Часто встречающиеся слова и выражения
a-synuclein acid activity Alzheimer Alzheimer's and Parkinson's Alzheimer's disease amyloid precursor protein Ann Neurol antibodies apoE apoptosis apoptotic Aẞ associated basal ganglia binding biochemical Biol brain cabergoline Cacabelos caspase cell death Chem cholinergic clinical cognitive cortex cortical degeneration dementia deposition disorders donepezil dopaminergic dopaminergic neurons drug dyskinesias dystonia Edited by Mizuno effects exon expression factors filaments function GAGs genetic glial hippocampus human immunoreactivity impairment increased induced inhibition inhibitors interaction kinase Kluwer Academic/Plenum Publishers L-dopa lesions levels levodopa Lewy bodies Mapping the Progress mechanism membrane molecular motor MPTP mutations neurodegenerative neurofibrillary tangles Neurology neurons neuroprotective Neurosci NFTs onset oxidative parkin Parkinson's disease Parkinson's Disease Edited parkinsonian pathology pathway peptide phenotype phosphorylation plaques presenilin Progress of Alzheimer's receptor role ẞAPP striatal striatum studies substantia nigra suggest symptoms synaptic synuclein therapeutic therapy toxic transgenic transgenic mice treatment ubiquitin vitro vivo y-secretase